Protective effect of total alkaloids of sophora alopecuroides on dextran sulfate sodium-induced chronic colitis

Chinese Journal of Integrative Medicine

Volumn 17, Issue 8, 2011, Pages 616-624

  Zhao, Wen Chang ^a   Song, Li Jun ^a   Deng, Hong Zhu ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Colitis; Dextran sulfate sodium; Nuclear factor?b signal transduction pathway; Total alkaloids of sophora alopecuroides

Indexed keywords

ALKALOID DERIVATIVE; ALOPERINE; DEXTRAN SULFATE; HAPTOGLOBIN; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRINE; OXYMATRINE; PLANT EXTRACT; SECRETORY IMMUNOGLOBULIN; SOPHOCARPINE; SOPHORA ALOPECUROIDES EXTRACT; SOPHORARAMINE; SOPHORIDINE; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; ALKALOID; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTECTIVE AGENT; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; CECUM; CHEMICAL COMPOSITION; CHROMATIN IMMUNOPRECIPITATION; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SOPHORA; SOPHORA ALOPECUROIDES; TISSUE LEVEL; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; ARTICLE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COLON; DOWN REGULATION; DRUG EFFECT; GENETICS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYTOTHERAPY; PROTEIN BINDING; ULTRASTRUCTURE;

ALKALOIDS; ANIMALS; CECUM; COLITIS; COLON; DEXTRAN SULFATE; DOWN-REGULATION; FEMALE; HAPTOGLOBINS; I-KAPPA B PROTEINS; IMMUNOGLOBULIN A, SECRETORY; INTERCELLULAR ADHESION MOLECULE-1; INTESTINAL MUCOSA; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PHYTOTHERAPY; PROMOTER REGIONS, GENETIC; PROTECTIVE AGENTS; PROTEIN BINDING; SIGNAL TRANSDUCTION; SOPHORA; TRANSCRIPTION FACTOR RELA;

EID: 84855172531     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-011-0813-0     Document Type: Review

References (30)

1. Bouma G, Strober W. The immunological and genetic basis of infl ammatory bowel disease. Nature 2003;3:521-534.
2. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;5717:1920-1925.
3. Podolsky DK. Infl ammatory bowel disease. N Engl J Med 2002;6:417-430.
4. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390-407.
5. Atreya I, Atreya R, Neurath MF. NF-κB in inflammatory bowel disease. J Intern Med 2008;263:591-596.
6. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, et al. Proteasome-mediated degradation of IκBα and processing of p105 in Crohn' disease and ulcerative colitis. J Clin Invest 2006; 12:3195-3203.
7. Han Y, Zhou Y, Liu Q. Ant iendotoxic ef fects of Sophora alopecuroides L. J Chin Med Mater (Chin) 2006;10:1066-1069.
8. Mou XL, Wang WB, Ba H, Alkber H, Liao LX. A review on the progress in the chemical compounds and pharmacology of Sophora alopecuroides L. J Xinjiang Normal Univ (Natural Sci Ed, Chin) 2005;1:45-50.
9. Zhao WC, Song LJ, Deng HZ. Research on preparation of guar-based hydrophilic matrix tablets containing total alkaloids of Sophora alopecuroides and its in vitro sophoridine release. Chin J Exp Tradit Med Formul (Chin) 2010;6:1-5.
10. Chen JG, Deng HZ. Effects of total base of Sophora alopecuroides on expression of SOD, MDA, NO, MPO in rats with experimental colitis. J Chin Mater Med (Chin) 2006;4:323-325.
11. Zhao W, Song L, Deng H, Yao H. Hydration, erosion and release behavior of guar-based hydrophilic matrix tablets containing total alkaloids of Sophora alopecuroides. Drug Dev Ind Pharm 2009;5:594-602.
12. Zhou Y, Wang H, Liang L, Zhao WC, Chen Y, Deng HZ. Total alkaloids of Sophora alopecuroides increases the expression of CD4+ CD25+ Tregs and IL-10 in rats with experimental colitis. Am J Chin Med 2010;2:265-277.
13. Zhao WC, Song LJ, Deng HZ. Amelioration of dextran sulfate sodium-induced chronic colitis by sulfasalazine salicylazosulfapyridine via reducing NF-κB transcription factor p65 recruitment to ICAM-1 gene promoters. Yakugaku Zasshi 2010;9:1-11.
14. Zhao WC, Song LJ, Deng HZ. Effect of sophoridine on dextran sulfate sodium-induced colitis in C57BL/6 mice. J Asian Nat Prod Res 2010;12:925-933.
15. Borm MEA, Bouma G. Animal models of inflammatory bowel disease. Drug Discov Today Dis Models 2004;1:437-444.
16. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004;50:81-92.
17. Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, et al. Therapeutic potency of IL-2 caspase-3 targeted treatment in a murine experimental model of inflammatory bowel disease (IBD) . Gut 2008;4:628-635.
18. Research Group of Guidance on GPT 3-1. Guidance on chronic toxicity testing in animals (rodent and nonrodent toxicity testing) for traditional Chinese medicine and naturally occurring drugs. 2005:3-16.
19. Lu YX, Lu JT, Chen MZ. Therapeutic effect of interleukin-10 on rat adjuvant arthritis. Chin Pharmacol Bull (Chin) 2000;16:103-107.
20. Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:G1328-G1338.
21. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71-78.
22. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006;314:1157-1162.
23. Danese S, Semeraro S, Marini M, Roberto I, Armuzzi A, Papa A, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis 2005;37:811-818.
24. Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005;288:G169-G174.
25. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-889.
26. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. J Intern Med 2005;35:419-426.
27. Ohkawara T, Nishihira J, Takeda H, Asaka M, Sugiyama T. Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J Gastroenterol 2005;40:117-122.
28. Mochizuki M, Hasegawa N. Therapeutic efficacy of pycnogenol in experimental inflammatory bowel diseases. Phytother Res 2005;12:1027-1028.
29. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
30. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;11:1061-1066.